Progyny Stock Price, News & Analysis (NASDAQ:PGNY) $36.26 -0.05 (-0.14%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$36.06▼$36.9650-Day Range$29.51▼$36.4552-Week Range$28.03▼$44.95Volume590,825 shsAverage Volume720,179 shsMarket Capitalization$3.48 billionP/E Ratio69.73Dividend YieldN/APrice Target$47.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Progyny MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside29.6% Upside$47.00 Price TargetShort InterestBearish6.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 7 Articles This WeekInsider TradingSelling Shares$1.30 M Sold Last QuarterProj. Earnings Growth19.30%From $0.57 to $0.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.92 out of 5 starsMedical Sector35th out of 954 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry1st out of 8 stocks 4.4 Analyst's Opinion Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, Progyny has a forecasted upside of 29.6% from its current price of $36.26.Amount of Analyst CoverageProgyny has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.87% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Progyny has recently increased by 8.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PGNY. Previous Next 2.3 News and Social Media Coverage News SentimentProgyny has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Progyny this week, compared to 3 articles on an average week.Search Interest4 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,301,826.00 in company stock.Percentage Held by Insiders14.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Progyny are expected to grow by 19.30% in the coming year, from $0.57 to $0.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 69.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 69.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.78.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 8.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Progyny Stock (NASDAQ:PGNY)Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More PGNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGNY Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comProgyny, Inc. (NASDAQ:PGNY) President Sells $433,314.48 in StockDecember 7, 2023 | americanbankingnews.comMark S. Livingston Sells 25,087 Shares of Progyny, Inc. (NASDAQ:PGNY) StockDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 4, 2023 | finance.yahoo.comReturns On Capital Are Showing Encouraging Signs At Progyny (NASDAQ:PGNY)December 1, 2023 | americanbankingnews.comProgyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNovember 21, 2023 | axios.comProgyny to birth new products across fertility, repro healthNovember 20, 2023 | finance.yahoo.comDoes Progyny (PGNY) have a Long Runway for Growth?November 16, 2023 | seekingalpha.comProgyny: Market Underappreciating Excellent QuarterDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Intellia Therapeutics (NTLA), Pfizer (PFE)November 13, 2023 | finance.yahoo.comProgyny (PGNY) is an Incredible Growth Stock: 3 Reasons WhyNovember 10, 2023 | finance.yahoo.comProgyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNovember 9, 2023 | finance.yahoo.comProgyny, Inc. (NASDAQ:PGNY) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Progyny (PGNY), DaVita (DVA) and Demant (OtherWILLF)November 8, 2023 | markets.businessinsider.comAnalyst Ratings for ProgynyNovember 7, 2023 | morningstar.comProgyny Inc PGNYNovember 7, 2023 | markets.businessinsider.comProgyny, Inc. Announces Third Quarter 2023 ResultsNovember 2, 2023 | nasdaq.com‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 StocksNovember 1, 2023 | finance.yahoo.comThe Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their FamiliesOctober 31, 2023 | finance.yahoo.comEarnings Preview: Progyny (PGNY) Q3 Earnings Expected to DeclineOctober 24, 2023 | finance.yahoo.comProgyny, Inc. Announces Details for Its Third Quarter 2023 Results ReportOctober 15, 2023 | seekingalpha.comProgyny: 4 Reasons I Bought This StockOctober 11, 2023 | finance.yahoo.comCould The Market Be Wrong About Progyny, Inc. (NASDAQ:PGNY) Given Its Attractive Financial Prospects?September 28, 2023 | nasdaq.comCanaccord Genuity Initiates Coverage of Progyny (PGNY) with Buy RecommendationSeptember 27, 2023 | finance.yahoo.comProgyny (PGNY): Unveiling Its True ValueSeptember 13, 2023 | benzinga.comCheck Out What Whales Are Doing With PGNYSeptember 1, 2023 | finance.yahoo.com3 Reasons Growth Investors Will Love Progyny (PGNY)See More Headlines Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees393Year Founded2008Price Target and Rating Average Stock Price Target$47.00 High Stock Price Target$57.00 Low Stock Price Target$34.00 Potential Upside/Downside+29.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.52 Trailing P/E Ratio69.73 Forward P/E Ratio63.61 P/E Growth1.43Net Income$30.36 million Net Margins5.03% Pretax Margin5.67% Return on Equity11.64% Return on Assets7.99% Debt Debt-to-Equity RatioN/A Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$1.03 billion Price / Sales3.36 Cash Flow$0.36 per share Price / Cash Flow100.53 Book Value$4.06 per share Price / Book8.93Miscellaneous Outstanding Shares95,836,000Free Float82,419,000Market Cap$3.48 billion OptionableNot Optionable Beta1.51 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. David J. Schlanger (Age 64)Executive Chairman Comp: $510.41kMr. Peter Anevski (Age 56)CEO & Director Comp: $1.01MMr. Michael Sturmer (Age 46)President Comp: $761.5kMr. Mark S. Livingston (Age 57)Chief Financial Officer Comp: $693.87kMs. Allison Swartz (Age 33)Executive VP, General Counsel & Secretary Comp: $173.35kMr. James HartVice President of Investor RelationsMs. Risa FisherExecutive VP & Chief Marketing OfficerMs. Cassandra PrattSenior VP of PeopleMs. Julie StadlbauerExecutive Vice President of Strategic Sales & PartnershipsMs. Janet Choi M.D.Member of the Medical Advisory Board & Chief Medical OfficerMore ExecutivesKey CompetitorsSotera HealthNASDAQ:SHCagilon healthNYSE:AGLTivity HealthNASDAQ:TVTYAmerican Renal AssociatesNYSE:ARAOntrakNASDAQ:OTRKView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 27,481 shares on 12/6/2023Ownership: 0.021%Michael E SturmerSold 12,696 sharesTotal: $433,314.48 ($34.13/share)Mark S LivingstonSold 25,087 sharesTotal: $868,511.94 ($34.62/share)American Century Companies Inc.Sold 55,793 shares on 11/30/2023Ownership: 1.276%Deutsche Bank AGBought 4,738 shares on 11/24/2023Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions PGNY Stock Analysis - Frequently Asked Questions Should I buy or sell Progyny stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks. What is Progyny's stock price target for 2024? 8 brokers have issued 1-year target prices for Progyny's stock. Their PGNY share price targets range from $34.00 to $57.00. On average, they expect the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts. How have PGNY shares performed in 2023? Progyny's stock was trading at $31.15 on January 1st, 2023. Since then, PGNY stock has increased by 16.4% and is now trading at $36.26. View the best growth stocks for 2023 here. When is Progyny's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our PGNY earnings forecast. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings data on Tuesday, November, 7th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The business earned $280.90 million during the quarter, compared to the consensus estimate of $271.20 million. Progyny had a net margin of 5.03% and a trailing twelve-month return on equity of 11.64%. The business's revenue was up 36.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.13 EPS. What ETFs hold Progyny's stock? ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Thrivent Small-Mid Cap ESG ETF (TSME), Harbor Corporate Culture Small Cap ETF (HAPS), Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Progyny issued on next quarter's earnings? Progyny issued an update on its fourth quarter earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $0.10-$0.11 for the period, compared to the consensus EPS estimate of $0.11. The company issued revenue guidance of $268.3-$276.3 million, compared to the consensus revenue estimate of $274.26 million. What is David Schlanger's approval rating as Progyny's CEO? 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD). When did Progyny IPO? (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's stock is owned by a number of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (4.11%), Fred Alger Management LLC (3.35%), Jennison Associates LLC (2.84%), JPMorgan Chase & Co. (2.56%), Riverbridge Partners LLC (1.97%) and Baillie Gifford & Co. (1.72%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Michael E Sturmer, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PGNY) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.